UCB Executive and Leadership Team

Charlotte Daehn, the Chief Financial Officer at UCB, directs global financial strategy and resource allocation. Daehn oversees all fiscal operations, including budgeting, forecasting, and financial reporting, ensuring robust financial health across the organization. This leadership position involves managing investment portfolios and optimizing capital structure to support UCB's research and development pipeline for neurological and autoimmune therapies. Charlotte Daehn drives financial discipline and strategic planning, aligning fiscal objectives with the company's mission to deliver innovative medicines to patients worldwide. The Chief Financial Officer's oversight extends to risk management and compliance, safeguarding UCB's assets and ensuring sustainable growth in a complex global market. Daehn's financial acumen is critical for funding UCB's expansion into new therapeutic areas and geographic regions, supporting the commercialization of key products like Cimzia and Vimpat.

Derek Xie, the Head Chief Financial Officer, Broad Market, Retail Distribution (China) at UCB, manages financial operations specifically for UCB's extensive activities within the Chinese market. Xie directs financial planning, analysis, and reporting tailored to the unique demands of China's broad market and retail distribution channels. This specialized financial leadership ensures that UCB's strategic investments and operational expenditures in China are optimized for maximum impact and compliance with local regulations. Derek Xie's responsibilities include overseeing the financial aspects of product launches and market penetration strategies for UCB's neurological and autoimmune therapies within this critical region. The Head Chief Financial Officer, Broad Market, Retail Distribution (China) plays a vital role in driving revenue growth and profitability, supporting UCB's global mission by strengthening its presence and operational efficiency in one of the world's largest pharmaceutical markets.

Steve Otten, the Market President at UCB, spearheads UCB's strategic initiatives and operational execution within a defined major market, likely focusing on the United States given UCB's significant presence there. Otten drives business development and ensures alignment of regional operations with UCB's global objectives in biopharmaceuticals. This leadership role involves overseeing commercial activities, market access, and policy engagement to facilitate patient access to UCB's innovative medicines for severe neurological and autoimmune conditions. Steve Otten directs the integration of UCB's scientific advancements with market needs, fostering growth and enhancing the company's reputation as a leader in its therapeutic areas. The Market President's responsibilities include managing key relationships with healthcare systems, payers, and regulatory bodies to support the successful commercialization of products like Keppra and Briviact, ultimately contributing to UCB's mission of improving patient lives.

Michael Davis, the Senior Vice President, Chief Marketing Officer, Head of Stakeholder Integration at UCB, architects comprehensive go-to-market strategies and enhances UCB's engagement with diverse stakeholder groups. Davis leads the marketing function, driving brand development and product commercialization for UCB's portfolio, which includes treatments for epilepsy, Parkinson's disease, rheumatoid arthritis, and Crohn's disease. The Head of Stakeholder Integration role involves fostering strong relationships with patient advocacy groups, healthcare providers, and policymakers to ensure UCB's medicines reach those in need. Michael Davis spearheads initiatives that integrate patient insights directly into the company's research and development processes, reinforcing UCB's patient-centric approach. This executive's purview includes shaping market perception and communicating the value of UCB's scientific advancements, particularly in neurology and immunology, across its global operations spanning over 40 countries.